Monte Rosa Therapeutics Inc (GLUE) — Institutional Holders Breakdown (Q2 2026)

GLUE ranks #3066 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

GLUE is a top-conviction position for Versant Venture Management, LLC — at 47.3% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in GLUE belongs to Price T Rowe Associates Inc /md/, but the position matters far more to Versant Venture Management, LLC, who has 47.3% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Price T Rowe Associates Inc /md/ has added to its GLUE position for two straight quarters, increasing it by $134.2M to reach $214.4M today.

Jane Street Group, LLC has trimmed its GLUE position for two straight quarters, cutting it by $3.2M while still holding $225.1K.

GLUE is down 1.2% today, but institutions show net buying of $227.1M this quarter — a divergence between today's price move and the underlying institutional flow.

GLUE reported a net loss of $38.6M in its latest fiscal year.

• Not yet profitable — net loss of $38.6M in the latest fiscal year
• Revenue grew 63.5% year over year
• Net income improved year over year, from -$72.7M to -$38.6M
• Operating cash flow was negative, using $22.8M in cash
• Current ratio of 6.12x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.93x equity — within a conventional range